Literature DB >> 27762517

Strategies for Better Hypertension Control in India and Other Lower Middle Income Countries.

Rajeev Gupta1, Raghuvir Singh Khedar2, Raja Babu Panwar3.   

Abstract

Hypertension is the most important cause of global burden of disease. It is highly prevalent in India and other low and lower-middle income countries. Prevalence of uncontrolled hypertension varies from 70-90% and is significantly greater in rural vs urban locations. Guidelines based treatment strategy has improved blood pressure (BP) control in high income countries but no context-specific guidelines exist in low and lower-middle income countries such as India. There are numerous barriers to proper BP control in these countries and include political apathy, bureaucratic inertia, weak health systems, overburdened healthcare providers and unempowered patients. Hypertension control can be improved in these countries by better political focus on social determinants of health such as education, development of health systems, proper healthcare financing, free or low-cost BP medicines, healthcare provider education for hypertension management, free primary care, task sharing with trained community health workers, patient empowerment and use of technological innovations. © Journal of the Association of Physicians of India 2011.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27762517

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  3 in total

Review 1.  Blood pressure control in diabetes-the Indian perspective.

Authors:  Vijay Viswanathan; T P Smina
Journal:  J Hum Hypertens       Date:  2019-05-17       Impact factor: 3.012

Review 2.  Hypertension: The most important non communicable disease risk factor in India.

Authors:  Rajeev Gupta; Denis Xavier
Journal:  Indian Heart J       Date:  2018-02-12

3.  Qualitative Study of Barriers to Adherence to Antihypertensive Medication among Rural Women in India.

Authors:  Shreya Gupta; Jas Pal Dhamija; Indu Mohan; Rajeev Gupta
Journal:  Int J Hypertens       Date:  2019-01-23       Impact factor: 2.420

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.